New Therapies for the Treatment of Renal Fibrosis
Authors:
- 9 August 2019
- book chapter
- Published by Springer Nature
- Vol. 1165, 625-659
Abstract
Renal fibrosis is the common pathway for progression of chronic kidney disease (CKD) to end stage of renal disease. It is now widely accepted that the degree of renal fibrosis correlates with kidney function and CKD stages. The key cellular basis of renal fibrosis includes activation of myofibroblasts, excessive production of extracellular matrix components, and infiltration of inflammatory cells. Many cellular mechanisms responsible for renal fibrosis have been identified, and some antifibrotic agents show a greater promise in slowing down and even reversing fibrosis in animal models; however, translating basic findings into effective antifibrotic therapies in human has been limited. In this chapter, we will discuss the effects and mechanisms of some novel antifibrotic agents in both preclinical studies and clinical trials.Keywords
This publication has 144 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor δ Agonist, HPP593, Prevents Renal Necrosis under Chronic IschemiaPLOS ONE, 2013
- Identification of a microRNA signature in renal fibrosis: role of miR-21American Journal of Physiology-Renal Physiology, 2011
- Periostin Is Induced in Glomerular Injury and Expressed de Novo in Interstitial Renal FibrosisThe American Journal of Pathology, 2011
- Distinct Actions of Endothelin A-Selective Versus Combined Endothelin A/B Receptor Antagonists in Early Diabetic Kidney DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Discoidin Domain Receptor 1 Is a Major Mediator of Inflammation and Fibrosis in Obstructive NephropathyThe American Journal of Pathology, 2011
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisKidney International, 2011
- Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of sclerodermaArthritis & Rheumatism, 2011
- Periostin mediates vascular smooth muscle cell migration through the integrins ανβ3 and ανβ5 and focal adhesion kinase (FAK) pathwayAtherosclerosis, 2010
- NADPH Oxidases: New Regulators of Old FunctionsAntioxidants & Redox Signaling, 2006
- Chemokines and chemokine receptors are involved in the resolution or progression of renal diseaseKidney International, 2003